Articles On Imugene (ASX:IMU)

Emyria announced progress on its MDMA (ecstasy) program Imugene gets green light for a Phase 2 Australian clinical trial Beamtree wins US$7m deal   Emyria Limited (ASX: EMD) has announced positive progress on its MDMA (also known as ‘ecst...

Immuno-oncology company Imugene (ASX:IMU) has announced it has received Human Research Ethics Committee approval to commence a Phase 2 clinical trial of its immunotherapy candidate, HER-Vaxx in Australia.

ASX to open extend losses as Wall Street crashes again Oil prices plunge 9% as EU ban on Russian oil fails to gain approval Aussie dollar plunges below US70c   The ASX 200 is set to extend its losses for a third consecutive day, following...

Imugene (IMU) receives Human Research Ethics Committee (HREC) approval to start a phase two clinical trial of its cancer vaccine, HER-Vaxx in Australia This approval confirms the company has completed pre-clinical safety and efficacy for t...

Highlights ASX 200 finished today’s session down 1.2% or 84.90 points to 7.120, The index was dragged lower by real estate, technology, and materials sectors. Rate worries, continued supply-side pressures, and a tightening lockdown in...

Imugene has rejected suggestions it was slow to update the market after copping its second notice from the ASX about the cancellation of a deal.

ASX 200 extended loss, down by 1.43% All sectors fell except for Energy Tech and Real Estate were the worst performers   The ASX has extended its selloff as local stocks closed to the lowest level in two months. At the close, the benchmar...

The share market closed at a seven-week low as soft Chinese economic data pushed the dollar below 70 US cents and sapped buying interest in mining stocks. The S&P/ASX 200 shed 85 points or 1.18 per cent. Today’s close was the weakest...

In late trade, the S&P/ASX 200 Index (ASX: XJO) looks set to record a disappointing decline. At the time of writing, the benchmark index is down 1.4% to 7,102.9 points. Four ASX shares that are falling more than most are listed below....

Healthcare and life sciences expert Scott Power – a senior analyst with Morgans Financial for 24 years – on what the movers and shakers have been doing in health and which ASX health stocks make Scott’s Powerplays. Are you the cuddly type?...

Highlights ASX 200 edged 0.8% higher today, snapping a three-day losing streak and mirroring gains in US markets. In the US, Federal Reserve increased rates by 50 basis points, dashing worries that it might raise rates by 75 basis poin...

Some of the worst-performing corners of the market enjoyed a day in the sun after a relief rally on Wall Street inspired the ASX’s first advance this week. Gold miners, tech companies and small and micro caps outperformed as the S&P/...

Tech and commodity stocks steered the share market towards its first gain of the week following Wall Street’s best session since 2020. The S&P/ASX 200 overcame an early wobble to advance 44 points or 0.6 per cent by mid-session. T...

At lunch on Thursday, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is pushing higher. The benchmark index is currently up 0.65% to 7,352.5 points. Here’s what is happening on the ASX 200 today: NAB half-year...

At lunch on Wednesday, the S&P/ASX 200 Index (ASX: XJO) has given back the majority of its morning gains and is just a fraction higher. The benchmark index is currently trading at 7,316.8 points. Here’s what is happening on the ASX 200...

The Imugene Limited (ASX: IMU) share price is moving in circles during Tuesday afternoon following an update from the company. At the time of writing, the immuno-oncology company’s shares are down 1.58% to 18.7 cents. It’s worth noting tha...

Highlights ASX 200 dropped 1.2% to close 88 points lower at 7347 with all sectors lower.  Investors await Reserve Bank of Australia’s (RBA) monthly monetary policy decision meeting tomorrow. US Federal Reserve and Bank of England migh...

ASX 200 closed 1.27% lower in a Tech-led rout All 11 sectors were in the red ahead of the RBA meeting tomorrow Property prices in Sydney and Melbourne have dropped for the first time since Covid started in 2020   Tech stocks plunged and l...

Central Banks have their fingers on the fun button this week, and the markets are pricing in the big push. The Emerging Companies Index (XEC) has been sunk on day dot, down 2.3%. The S&P/ASX 200 index was down 1.2% at 4.15pm, with this...

Tech stocks slumped to an eight-week low as turmoil on Wall Street and caution ahead of a potential rate rise tomorrow fuelled a sharp share market retreat. The S&P/ASX 200 declined 88 points or 1.18 per cent. The tech sector shed al...

The Imugene Limited (ASX: IMU) share price is deep in the red today following a shock announcement from the company. At the time of writing, the immuno-oncology company’s shares are down 15% to 18.7 cents apiece. It’s worth noting that Imu...

Imugene (IMU) has scrapped its supply agreement with Merck & Co tradename MSD The parties joined forces in March to collaborate on a clinical trial assessing the safety and efficacy of IMU’s HER-Vaxx immunotherapy in combination with M...

The share market shed 100 points after Wall Street’s worst session since 2020 ensured the new month got off to a rocky start. Tech and property stocks spearheaded losses as the S&P/ASX 200 fell 101 points or 1.36 per cent by mid-sess...

A broad rally carried the share market towards a second day of gains at the end of a challenging month for investors. All 11 sectors rose as the S&P/ASX 200 put on 58 points or 0.79 per cent. The advance trimmed the index’s loss for...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

ASX was down for third consecutive day Australia CPI was higher than expected at 5.1% Tech, consumer staples got smashed in a broad brushed selloff    ASX Tech stocks tumbled by over 2% today, as the possibility of a May rate hike gains m...

Prescient Thereapeutics gives hope with its personalised Car-T cell therapy Imugene working to activate the immune systems of cancer suffers to fight disease Rhythm Bioscience revolutionising the detection of bowel cancer According to th...

ASX 200 fell 1.5% and finished the week lower by  The Mining Index had its largest weekly drop since August Markets have been spooked after hawkish US Fed comments overnight   It was carnage across the board as local shares took a direct...

Highlights ASX200 closes trade about 0.56% higher at 7565.20 points today (19 April 2022). The Australian benchmark shrugged off global market weakness and overnight fall in the US market. Healthcare remained the top loosing sector on...

Local blue chips have gone into the Easter Break back in the green. The ASX 200 was up 44.4 points to 7,523.4 at close of trade. The ASX followed the lead of Wall Street overnight, which rallied and broke this week’s losing streak.All major...

Highlights ASX stocks trade in the green today (14 April 2022, 12 PM AEST) ahead of Easter festivities . Utilities remains the best performer amongst all the industrial sectors that are on a gaining spree. The ASX200 gained about 0...

Highlights The benchmark ASX 200 index was trading 0.44% up at 7,512 in the first 10 minutes of trading. Wall Street rallied to close higher on Wednesday. The materials and utilities sectors were enjoying the most gains, rising 0.54%...

Clinical stage immuno-oncology company Imugene (ASX:IMU) says City of Hope in the US has dosed the first cohort two patient in the Phase I clinical trial of the company's oncolytic virotherapy candidate.

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

ASX rallies after opening lower today Energy stocks lead the pack on higher oil prices Australia CPI is due tomorrow   Local blue chips brushed off early jitters to finish the day higher by 0.32%. The ASX was bracing for another day of lo...

Highlights The benchmark ASX 200 index was trading 0.25% up at 7,473 in the first 15 minutes of trading. US inflation rose to 8.5% in March 2022, highest since 1981. PointsBet’s wholly owned subsidiary PointsBet Pennsylvania LLC has s...

Highlights ASX 200 fell 0.4%, or 31.2 points, to 7454, weighed down by losses across healthcare and technology sectors. Market sentiments are being powered by developments around Russia-Ukraine war and heightened inflationary concerns...

ASX 200 slipped 0.42% Russia bonds deemed to have defaulted by S&P Afterpay net loss is growing  Local shares slipped by 0.42% today on growing concerns that imminent rate hikes could trigger a revaluation of equities. It was a sea of...

The Australian share market fell to its lowest in two weeks after a global retreat from risk lowered commodity prices and US equities. The S&P/ASX 200 finished 31 points or 0.42 per cent in the red at 7454 after trading as low as 743...

A broad sell-off lowered Australian shares in the wake of sharp declines on Wall Street and commodity markets overnight. The S&P/ASX 200 declined steadily to a mid-session loss of 40 points or 0.53 per cent. All 11 sectors retreat...

ASX 200 healthcare shares have struggled for the past six months, let’s face it. After peaking at 52-week highs of 47,760 back in September 2021, the S&P/ASX 200 Health Care Index (ASX: XHJ) now rests at 39,861. That’s a 16.5% decline...

ASX was down 0.5% The US Fed signals tightening Aussie payrolls jobs almost flat in March   The ASX followed Wall Street into the red, falling by 0.60% as market sentiment turned sour following some Fed news overnight. Minutes from the la...

The share market fell for a second day as global financial markets continued to adjust to a fast-changing rates outlook. The S&P/ASX 200 dropped 47 points or 0.63 per cent to its lowest close in a week and a half. Rate-sensitive g...

ASX 200 is within striking range of record level Tech sector jumps 3% RBA keeps cash rate at 0.1% Local blue chip shares closed flat despite a big rally in Tech stocks. The ASX 200, currently at 7,516, is now within range of its record le...

ASX 200 extends winning streak US bonds have sharply inverted, sparking concerns of a potential recession China says it has found a new Omicron sub-variant   It was a sea of green today on the ASX, as local investors shrugged off a rapid...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Highlights ASX 200 inched 0.2% lower after news that Australia would impose a 35% tariff on Russian imports. Despite the fall, ASX 200 ended March 2022 with a healthy gain of over 6%. Investors globally are tracking updates about the...

The healthcare sector is Australia’s biggest employer, employing 1 in 7 Aussies or roughly two million people. Treasurer Josh Frydenberg announced last night that Australia’s health budget will top $132bn in 2022-23, up from $62bn a decade...

eInvest MD Camilla Love discusses five ways to spot whether your ESG investment manager is authentic Apostle’s Fiona Manning talks about the new People and Planet Fund, which takes a zero-tolerance approach to ESG investing The Ethical In...

The Imugene Limited (ASX: IMU) share price is on the move today. This comes after the company announced an update on its phase 1 clinical trial of its oncolytic virotherapy candidate, Checkvacc. Checkvacc is a novel treatment currently be...